Suchergebnisse - "De Giorgi, Ugo"

PubPharm (596)

61

Global Real-World Outcomes of Patients Receiving Immuno-Oncology Combinations for Advanced Renal Cell Carcinoma: The ARON-1 Study

enthalten in: Targeted oncology | 2023

von Santoni, M. | Massari, F. | Myint, Z. | +53

62

The role of the caregiver in older patients with advanced prostate cancer : results from the ADHERE Prospective Study of the Meet-URO network

enthalten in: Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer | 2023

von Giunta, E. | De Padova, S. | Anpalakhan, S. | +18

63

The role of the caregiver in older patients with advanced prostate cancer: results from the ADHERE Prospective Study of the Meet-URO network

enthalten in: Supportive care in cancer | 2023

von Giunta, E. | De Padova, S. | Anpalakhan, S. | +18

64

The role of the caregiver in older patients with advanced prostate cancer: results from the ADHERE Prospective Study of the Meet-URO network

enthalten in: Supportive care in cancer | 2023

von Giunta, E. | De Padova, S. | Anpalakhan, S. | +18

65

A novel immunotherapy prognostic score for patients with pretreated advanced urInary TrAct CArcinoma from the subgroup analysis of the SAUL study : the ITACA Score

enthalten in: Minerva urology and nephrology | 2023

von Fornarini, G. | Rebuzzi, S. | Buti, S. | +18

66

Real-world effectiveness of pembrolizumab as first-line therapy for cisplatin-ineligible patients with advanced urothelial carcinoma: the ARON-2 study

enthalten in: Cancer immunology immunotherapy | 2023

von Santoni, M. | Myint, Z. | Büttner, T. | +40

67

Real-world effectiveness of pembrolizumab as first-line therapy for cisplatin-ineligible patients with advanced urothelial carcinoma: the ARON-2 study

enthalten in: Cancer immunology immunotherapy | 2023

von Santoni, M. | Myint, Z. | Büttner, T. | +40

68

Cabozantinib plus Nivolumab and Ipilimumab in Renal-Cell Carcinoma

enthalten in: The New England journal of medicine | 2023

von Choueiri, T. | Powles, T. | Albiges, L. | +116

CommentIn: Eur Urol. 2023 Oct;84(4):e93. - PMID 37442718

69

Tailoring treatment with cabozantinib or pazopanib in patients with metastatic renal cell carcinoma : does it affect outcome?

enthalten in: Expert review of anticancer therapy | 2023

von Corianò, M. | Giannarelli, D. | Scartabellati, G. | +21

70

INOVATYON/ ENGOT-ov5 study : Randomized phase III international study comparing trabectedin/pegylated liposomal doxorubicin (PLD) followed by platinum at progression vs carboplatin/PLD in patients with recurrent ovarian cancer progressing within 6-12 months after last platinum line

enthalten in: British journal of cancer | 2023

von Colombo, N. | Gadducci, A. | Sehouli, J. | +139